Greg has spent the last decades working full time with early stage companies as a super angel, board member, lead investor, and advisor. Greg is a partner in Saunders Murdock Associates, a super angel partnership that invests in early stage life science companies. In this role, Greg is actively involved in many portfolio companies where he works with CEO’s on strategy, fundraising and communications. Saunders Murdock Associates LLC has made multiple investments, building a portfolio of approximately 25 early stage companies sourced from Boston, MA and Louisville, KY and is affiliated with XLerateHealth in Louisville, KY and Flint, MI. The focus of this portfolio is life science companies.
Dr. Bernard M. Peperstraete is CEO and co-founder of Acuamark Diagnostics, Inc. Bernard is a medical entrepreneur, and has been involved in operating in, founding and investing in life science businesses for over 20 years; Prior to Acuamark, Bernard ran ACT Biotech, a cancer pharmaceutical company (acquired by Eddingpharm). Earlier, Bernard was involved in healthcare venture capital for nearly a decade, most recently as a Partner at NGN Capital. Bernard served on the boards of Exosome Diagnostics (acquired by Bio-Techne), ACT Biotech and Potentia Pharma (aka APLS:NASDAQ), and was closely involved with a number of transactions, e.g. Santhera (SANN:SIX) and Artisan Pharma (acquired by AKP). Before completing his MBA at Harvard, Bernard worked on emerging market opportunities at Novartis in Basel, was a Deputy Director at the Tan Tock Seng Hospital in Singapore (during the SARS crisis) and successfully co-founded and ran a contract research business, also in Singapore. In 1999, after serving as a physician, Dr. Peperstraete managed the HIV business unit at Bristol Myers & Squibb, Singapore. MD, Katholieke Universiteit Leuven, Belgium; DTMIH, Institute of Tropical Medicine, Belgium MBA, Harvard Business School.